If you’re looking for a reason why INOVIQ (ASX:IIQ) shares jumped 6% out the gate on Tuesday, it’s this – after announcing similar success for Alzheimer’s patients in June, the company now says it can test blood for Parkinson’s. it all boils down to Inoviq’s software-based proprietary platform, ‘NEURO-NET,’ which ultimately creates a computerised “protein fingerprint” from blood sample data that can differentiate between donors with “normal healthy blood” and those with target conditions. Both Alzheimer’s Disease (AD), and now Parkinson’s Disease (PD), are target conditions INOVIQ states NEURO…
